A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

NCT01239017 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Osteoarthritis

Interventions

BIOLOGICAL: REGN475
OTHER: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]